Text Box: devoted to high quality products and services Matriks Biotek

 

Hacettepe Teknokent

Kulucka Merkezi

Ar-Ge Binasý No: 5

Ankara

Türkiye

To contact us:

Phone:     +90 (312) 397 64 99

Fax:          +90 (312) 397 55 42

E-mail:     info@matriksbiotek.com

                 product@matriksbiotek.com

                 oem@matriksbiotek.com

                 service@matriksbiotek.com

 

 

 
Text Box:

Q-ATI

Antibody to Infliximab

(ATI) ELISA

Improved Sensitivity

Now detects at least 7 ng/ml ATI

 

 

 

Q-INFLIXI

 

 

 
Text Box: DDW week 2009: the anti-TNF battle  Response prediction and switching Only approximately 60% of patients respond to TNF inhibition. Consequently, research is focusing on predictors of response (biomarkers, composite assessment tools etc). By 2012, the ability to predict response will be shaping the autoimmune market, driven by cost efficiency and applicable to both biologics and small molecule products. Previous opinion has considered that the optimization of infliximab Remicade is key before switching, but a presentation by Waqqas Afif suggested otherwise. He found that assessing the infliximab level and status of human anti-chimeric antibodies (HACAs) was useful and impacted clinical management. While increasing the dose in patients with non-therapeutic infliximab Remicade levels may be more effective than switching to another anti-TNF agent, this strategy did not work in patients who had HACAs. Afif concluded that changing treatment based on clinical symptoms alone may lead to inappropriate management. Datamonitor predicts that improvements in serum tests and biomarker assessment (e.g. using Prometheus IBD diagnostic assays to verify non-response) will be key in the next few years, and will drive therapy choice from about 2012 onwards. Text Box: “USE YOUR DRUG EFFECTIVELY AND SAFELY” Follow-up your patient’s dose response to infliximab with Q-INFLIXI(*) and adjust dose when needed. Check anti-infliximab antibodies in your patients sera with Q-ATI(*) , escalate the dose or combine with (e.g.) methotrexate when needed. (*) For research use only, laboratories or clinics should validate the kits according to their needs

Q-ETA

 

Etanercept ELISA

 

 

 
NEWText Box: Q-ETA Etanercept specific monoclonal antibody based Enzyme immunoassay for the quantitative determination of etanercept (Enbrel®) in serum and plasma samples between the Cmin and Cmax range of concentrations as indicated. The user-friendly Matriks Biotek Q-ETA is the first and only ELISA kit in the market for the quantitative determination of etanercept (Enbrel®) at uppermost specificity.

Infliximab ELISA

 

 

 

Q-ADA

 

Adalimumab ELISA

 

 

 
NEWText Box: Q-ADA Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma. Matriks Biotek adalimumab ELISA has been especially developed for the quantitative analysis of free adalimumab in serum and plasma samples.